Mealey's (May 12, 2020, 3:25 PM EDT) -- WASHINGTON, D.C. — Defending a discovery process established in a multidistrict litigation over generic drug price-fixing, a group of respondents, headed up by a coalition of state attorneys general (AGs) filed a brief on May 11 asking the U.S. Supreme Court to deny a petition for certiorari in which a collection of generic drug manufacturers claim that the process violates Federal Rule of Civil Procedure 26(b)(1) by not giving them the chance to object to discovery materials prior to submission on the basis of relevance or responsiveness (Actavis Holdco Inc., et al. v. Connecticut, et al., No. 19-1010, U.S. Sup.)....